Cameron John Reynolds Buys 78,125 Shares of VolitionRx Limited (NYSE:VNRX) Stock

Key Points

• CEO Cameron John Reynolds purchased 78,125 shares of VolitionRx Limited at an average price of $0.64 per share, totaling approximately $50,000.
• The company's stock has a market capitalization of $67.59 million and has recently traded slightly up, reaching $0.65 per share.
• Analysts have issued mixed ratings for VolitionRx, with a consensus price target of $3.50 and varying recommendations ranging from sell to strong buy.

VolitionRx Limited (NYSE:VNRX - Get Free Report) CEO Cameron John Reynolds bought 78,125 shares of the firm's stock in a transaction dated Tuesday, August 5th. The stock was purchased at an average cost of $0.64 per share, for a total transaction of $50,000.00. Following the transaction, the chief executive officer directly owned 2,609,847 shares of the company's stock, valued at $1,670,302.08. The trade was a 3.09% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Cameron John Reynolds also recently made the following trade(s):

• On Thursday, June 12th, Cameron John Reynolds purchased 12,500 shares of VolitionRx stock. The stock was acquired at an average price of $0.59 per share, for a total transaction of $7,375.00.
• On Monday, May 19th, Cameron John Reynolds bought 20,000 shares of VolitionRx stock. The shares were acquired at an average price of $0.44 per share, for a total transaction of $8,800.00.

VolitionRx Stock Performance

Shares of NYSE:VNRX traded up $0.00 during mid-day trading on Friday, reaching $0.64. 56,031 shares of the company's stock were exchanged, compared to its average volume of 195,362. The firm has a market capitalization of $66.76 million, a price-to-earnings ratio of -1.78 and a beta of 1.26. The business's fifty day moving average price is $0.69 and its 200-day moving average price is $0.59. VolitionRx Limited has a twelve month low of $0.40 and a twelve month high of $0.94.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Blair William & Co. IL acquired a new position in VolitionRx in the second quarter valued at $30,000. Silverberg Bernstein Capital Management LLC raised its holdings in shares of VolitionRx by 42.8% during the second quarter. Silverberg Bernstein Capital Management LLC now owns 200,782 shares of the company's stock valued at $153,000 after purchasing an additional 60,209 shares during the period. Millennium Management LLC acquired a new position in shares of VolitionRx during the fourth quarter valued at about $36,000. Lagoda Investment Management L.P. raised its stake in VolitionRx by 24.3% during the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company's stock worth $4,546,000 after buying an additional 1,481,000 shares during the period. Finally, Northern Trust Corp raised its position in shares of VolitionRx by 32.0% during the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company's stock worth $71,000 after purchasing an additional 28,579 shares during the period. 8.09% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently issued reports on VNRX. Jones Trading raised VolitionRx to a "strong-buy" rating and set a $3.00 price target on the stock in a research report on Tuesday, June 10th. Wall Street Zen began coverage on VolitionRx in a report on Thursday, May 15th. They set a "sell" rating on the stock. Finally, D. Boral Capital reissued a "buy" rating and set a $5.00 price objective on shares of VolitionRx in a report on Thursday, July 17th. One analyst has rated the stock with a sell rating, one has given a hold rating, two have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $3.50.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.